Kymera Therapeutics Insider Sold Shares Worth $295,949, According to a Recent SEC Filing-February 2024-www.financetom.com

Kymera Therapeutics Insider Sold Shares Worth $295,949, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Kymera Therapeutics Insider Sold Shares Worth $295,949, According to a Recent SEC Filing

Oct 14, 2025 7:47 AM

10:02 AM EDT, 10/14/2025 (MT Newswires) -- Jeffrey W. Albers, Director, on October 13, 2025, sold 5,000 shares in Kymera Therapeutics ( KYMR ) for $295,949.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1815442/000119312525238130/xslF345X05/ownership.xml

Price: 59.13, Change: -0.77, Percent Change: -1.28

Previous page： Murdoch's REA ends month-long takeover pursuit of Britain's Rightmove Next page： RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Murdoch's REA ends month-long takeover pursuit of Britain's Rightmove

Oct 2, 2024

By Aby Jose Koilparambil (Reuters) -Rightmove's shares dropped 8% on Monday after Rupert Murdoch's REA Group ended its $8.29 billion takeover pursuit following a fourth bid rejection from the British real estate portal. Australian property listing firm REA's decision to walk away from making a formal offer for Rightmove ahead of a 1600 GMT deadline capped a month-long saga that...

RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib

Oct 2, 2024

08:34 AM EDT, 09/30/2024 (MT Newswires) -- RedHill Biopharma ( RDHL ) said Monday that the US has issued a new patent for identifying a novel biomarker of coronavirus pneumonia prognostic for potential opaganib efficacy for the treatment of COVID-19. The patent from the US Patent and Trademark Office would be granted on Oct. 15 and be valid through 2041,...

Mobix Labs Proposes All-Cash Offer for Emcore

Oct 2, 2024

08:36 AM EDT, 09/30/2024 (MT Newswires) -- Mobix Labs ( MOBX ) said Monday it has submitted a non-binding cash offer to acquire Emcore ( EMKR ) shares for $3.80 per share. The company said the acquisition represents a more than 200% premium over Emcore's ( EMKR ) Sept. 27 stock closing price. Mobix Labs' ( MOBX ) board of...

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Oct 2, 2024

On Monday, Prime Medicine Inc. ( PRME ) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co ( BMY ) to develop reagents for the next generation of ex vivo T-cell therapies. Under the terms of the agreement, Prime Medicine ( PRME ) will design optimized Prime Editor reagents for a select number of targets, including reagents...